List View

Displaying 1 - 25 of 2,346

AML- Where Are We Now and Where Are We Going

Advancing Precision In Endometrial Carcinoma Molecular Classification And Its Impact On Prognosis And Treatment. Are We Ready

Adjuvant Therapy for Renal Cell Carcinoma- Hope or Hype

Melanoma- Have we Hit a Plateau or are we Making Progress

Treating Advanced Or Metastatic Cervical Cancer ADCs, VEGF Inhibitors, And Immunotherapy

Immunotherapy For Uterine Cancer New Standards For Upfront Treatment For Advanced Or Recurrent Disease

Controversies In The Management Of Ovarian Cancer A Focus On First Line Treatment

Immunotherapy For Triple Negative Breast Cancer Optimal Chemotherapy Partners, New Directors, And Managing Toxicity

Advances in the Treatment of High Risk Early Stage Hormone Receptor Positive Breast Cancer

Antibody Drug Conjugates- New Directions, New Agents!

Sequencing Endocrine Therapy And Targeted Agents For The Treatment Of Hormone Receptor Positive Metastatic Breast Cancer

PARP Inhibitors in Prostate Cancer- Who, When, and Why (not)

Updates in Systemic Therapy of Urothelial Cancer

Small Cell Lung Cancer

Neoadjuvant and Adjuvant Immunotherapy

What’s New in EGFR, ALK, RET and c-MET

New Agents after Immunotherapy Resistance

New Approaches And Advances In The Therapy Of Gliomas

Immunotherapy in HCC

Molecular and Immunotherapy Updates in Colon Cancer

Gene Therapy in Oncology: Past, Present and Future

Payor Benefits Design Changing Oncology Care Delivery

Update on Novel Therapies for NHL

Role of Immunotherapy in Myeloma

Update on Therapy Options for Untreated and Relapsed CLL